Medipal Holdings Corp distributes pharmaceuticals and health and beauty products to medical institutions and retailers... Show more
MEPDF saw its Momentum Indicator move above the 0 level on July 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator turned positive. In of the 12 cases, the stock moved higher in the following days. The odds of a move higher are at .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for MEPDF just turned positive on July 22, 2025. Looking at past instances where MEPDF's MACD turned positive, the stock continued to rise in of 13 cases over the following month. The odds of a continued upward trend are .
MEPDF moved below its 50-day moving average on June 20, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MEPDF crossed bearishly below the 50-day moving average on July 02, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for MEPDF entered a downward trend on July 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MEPDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.647) is normal, around the industry mean (7.892). P/E Ratio (12.285) is within average values for comparable stocks, (29.460). MEPDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). Dividend Yield (0.027) settles around the average of (0.032) among similar stocks. P/S Ratio (0.112) is also within normal values, averaging (35.215).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors